Metronomic capecitabine inhibits liver transplant rejection in rats by triggering recipients’ T cell ferroptosis

Figure 1 Metronomic capecitabine showed no significant myelosuppression. A and B: Hemoglobin level and platelets count in the peripheral blood; C-F: White blood cells, lymphocytes, granulocytes, and monocytes counts in the peripheral blood; G: Bone marrow tissue was stained with hematoxylin and eosin (50 × and 200 ×). Statistical analysis was done by unpaired t-test, n = 6. Data are shown as mean ± SD; ^bP < 0.01 vs the control group. CON: Untreated control groups, rats received 0.9% normal saline for 7 d; MET: Metronomic capecitabine (CAP)-treated groups, rats received metronomic CAP (100 mg/kg/d) treated for 7 d; HGB: Hemoglobin; PLT: Platelets; WBC: White blood cells; lymph: Lymphocytes; Gran: Granulocytes; Mon: Monocytes.